NCT04172844 (PAVE) is a Phase 1 clinical trial of Azacitidine in Acute Myelogenous Leukemia, sponsored by Medical College of Wisconsin.

Who is sponsoring NCT04172844?

NCT04172844 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT04172844?

Interventions in NCT04172844: Azacitidine, Venetoclax, Pevonedistat.

What condition does NCT04172844 study?

NCT04172844 studies Acute Myelogenous Leukemia.

Is NCT04172844 still recruiting?

NCT04172844 is currently terminated. Last updated 4 June 2024.

Last reviewed 2024-06-04 · How we verify

NCT04172844: PAVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

Terminated Phase 1 Last updated 4 June 2024

What this trial tests

Phase 1 trial testing Azacitidine in Acute Myelogenous Leukemia in 16 participants. Terminated before completion.

Timeline

13 January 2020

Primary endpoint
12 December 2021

27 February 2022

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	13 January 2020
Primary completion	12 December 2021
Estimated completion	27 February 2022
Sites	2 locations across United States

Drugs / interventions tested

Azacitidine (azacitidine) — full drug profile →
Venetoclax (venetoclax) — full drug profile →
Pevonedistat — full drug profile →

Conditions studied

Acute Myelogenous Leukemia — all drugs for Acute Myelogenous Leukemia →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Acute Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions.
Fu DJ, Wang T. · · 2023 · cited 45× · PMID 37525282 · DOI 10.1186/s13045-023-01485-7
Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis.
Islam Z, Ali AM, Naik A, Eldaw M, et al · · 2021 · cited 38× · PMID 34195082 · DOI 10.3389/fonc.2021.681377
Targeting cullin neddylation for cancer and fibrotic diseases.
He ZX, Yang WG, Zengyangzong D, Gao G, et al · · 2023 · cited 33× · PMID 37771770 · DOI 10.7150/thno.78876
Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways.
Liu D, Che X, Wu G. · · 2024 · cited 25× · PMID 38191508 · DOI 10.1186/s40364-023-00545-x
Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
El-Cheikh J, Bidaoui G, Saleh M, Moukalled N, et al · · 2023 · cited 22× · PMID 37071328 · DOI 10.1007/s44228-023-00041-x
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Murthy GSG, Saliba AN, Szabo A, Harrington A, et al · · 2024 · cited 17× · PMID 38572562 · DOI 10.3324/haematol.2024.285014
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Saliba AN, Kaufmann SH, Stein EM, Patel PA, et al · · 2023 · cited 16× · PMID 36315007 · DOI 10.1182/bloodadvances.2022008625
Advances in therapeutic options for newly diagnosed, high-risk AML patients.
Doucette K, Karp J, Lai C. · · 2021 · cited 16× · PMID 33995985 · DOI 10.1177/20406207211001138

Verify or expand the search:

Other trials of Azacitidine

Trials testing the same drug.

NCT07508982 — Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML · Phase 1, PHASE2 · not yet recruiting
NCT05554419 — Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Tr · Phase 2 · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting

Other recruiting trials for Acute Myelogenous Leukemia

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting
NCT05974150 — Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04172844 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 4 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04172844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing